A phase II trial of olanzapine, dexamethasone, and palonosetron for the prevention of chemotherapy-induced nausea and vomiting: a Hoosier oncology group study

[1] Aapro MS(2006)A phase III, double blind, randomized trial of palonosetron compared with ondansetron in preventing chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy Ann Oncol 17 1441-1449

[2] Grunberg SM(2001)Antipsychotic-associated weight gain: a review of the literature J Clin Psychiatry 62 22-31

[3] Manikhas GM(2006)Delayed nausea and vomiting continue to reduce patients’ quality of life alter highly and moderately emetogenic chemotherapy despite antiemetic treatment J Clin Oncol 24 4472-4478

[4] Allison DB(1996)Radioreceptor binding profile of the atypical antipsychotic olanzapine Neuropsychopharmacology 14 87-96

[5] Casey DE(2001)Potent antagonism of 5HT3 and 5HT6 receptors by olanzapine Eur J Pharmacol 430 341-349

[6] Bloechl-Daum B(2000)Assessing symptom distress in cancer patients: the M.D. Anderson Symptom Inventory Cancer 89 1634-1646

[7] Deuson RR(2003)Improved prevention of moderately emetogenic chemotherapy-induced nausea and vomiting with palonosetron, a pharmacologically novel 5HT3 receptor antagonist: results of a phase III, single dose trial versus dolasetron Cancer 98 2473-2482

[8] Panagiotis M(2004)Efficacy, safety, and pharmacokinetics of palonosetron in patients receiving highly emetogenic, cisplatin-based chemotherapy: a dose-ranging, clinical study Ann Oncol 15 330-337

[9] Bymaster FP(2004)Use of atypical antipsychotic agents for symptom control in patients with advanced cancer J Support Oncol 2 447-452

[10] Calligaro D(1999)New-onset diabetes mellitus and diabetic ketoacidosis associated with olanzapine treatment Psychosomatics 40 438-443

[1] Aapro MS(2006)A phase III, double blind, randomized trial of palonosetron compared with ondansetron in preventing chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy Ann Oncol 17 1441-1449

[2] Grunberg SM(2001)Antipsychotic-associated weight gain: a review of the literature J Clin Psychiatry 62 22-31

[3] Manikhas GM(2006)Delayed nausea and vomiting continue to reduce patients’ quality of life alter highly and moderately emetogenic chemotherapy despite antiemetic treatment J Clin Oncol 24 4472-4478

[4] Allison DB(1996)Radioreceptor binding profile of the atypical antipsychotic olanzapine Neuropsychopharmacology 14 87-96

[5] Casey DE(2001)Potent antagonism of 5HT3 and 5HT6 receptors by olanzapine Eur J Pharmacol 430 341-349

[6] Bloechl-Daum B(2000)Assessing symptom distress in cancer patients: the M.D. Anderson Symptom Inventory Cancer 89 1634-1646

[7] Deuson RR(2003)Improved prevention of moderately emetogenic chemotherapy-induced nausea and vomiting with palonosetron, a pharmacologically novel 5HT3 receptor antagonist: results of a phase III, single dose trial versus dolasetron Cancer 98 2473-2482

[8] Panagiotis M(2004)Efficacy, safety, and pharmacokinetics of palonosetron in patients receiving highly emetogenic, cisplatin-based chemotherapy: a dose-ranging, clinical study Ann Oncol 15 330-337

[9] Bymaster FP(2004)Use of atypical antipsychotic agents for symptom control in patients with advanced cancer J Support Oncol 2 447-452

[10] Calligaro D(1999)New-onset diabetes mellitus and diabetic ketoacidosis associated with olanzapine treatment Psychosomatics 40 438-443